Novartis has scooped up the ex-U.S. rights to Ophthotech’s Fovista–its late-stage therapy for wet age-related macular degeneration that hopes to one day rival heavyweight franchises controlled by Roche and Regeneron–in a package deal potentially worth more than $1 billion.

…read more

Source: Novartis hands Ophthotech a $1B deal for heavyweight wet AMD contender


0 No comments